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Abstract
Introduction: Despite continuous efforts, not a single predictor of breast cancer chemotherapy resistance has made it into
the clinic yet. However, it has become clear in recent years that breast cancer is a collection of molecularly distinct diseases.
With ever increasing amounts of breast cancer data becoming available, we set out to study if gene expression based
predictors of chemotherapy resistance that are specific for breast cancer subtypes can improve upon the performance of
generic predictors.
Methods: We trained predictors of resistance that were specific for a subtype and generic predictors that were not specific
for a particular subtype, i.e. trained on all subtypes simultaneously. Through a rigorous double-loop cross-validation we
compared the performance of these two types of predictors on the different subtypes on a large set of tumors all profiled
on the same expression platform (n = 394). We evaluated predictors based on either mRNA gene expression or clinical
features.
Results: For HER2+, ER2 breast cancer, subtype specific predictor based on clinical features outperformed the generic, non-
specific predictor. This can be explained by the fact that the generic predictor included HER2 and ER status, features that are
predictive over the whole set, but not within this subtype. In all other scenarios the generic predictors outperformed the
subtype specific predictors or showed equal performance.
Conclusions: Since it depends on the specific context which type of predictor – subtype specific or generic- performed
better, it is highly recommended to evaluate both specific and generic predictors when attempting to predict treatment
response in breast cancer.
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Introduction
Breast cancer is a heterogeneous disease, which can be
subdivided into distinct subtypes. Based on clinical features,
including age, tumor grade, and TNM stage, patients can be
stratified into more homogeneous subgroups. By measuring
estrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) expression, we can
stratify tumors into a HER2 positive set (HER2+, either ER+ or
ER2), a Luminal set (HER22, ER+) and a Triple Negative set
(HER22, ER2, PR2; TN). These three different subtypes of
breast cancer are considered distinct diseases and are approached
accordingly in the clinic. Breast cancer patients of all subtypes
receive chemotherapy as part of the treatment process.
Neoadjuvant therapy, the administration of therapeutic agents
before the main treatment (typically surgery), reduces the mortality
of breast cancer patients [1]. However, some patients only
experience the downside of the therapy (i.e. toxicity) and not the
benefit (i.e. increased survival). It has been shown that patients
who achieve a pathological complete response after neoadjuvant
treatment have a higher chance of relapse free survival [2,3].
Because neoadjuvant treatments can be very toxic and not all
patients benefit from the treatment, it would be desirable if the
non-responders to therapy can be accurately separated from the
responders. Multiple approaches to predict the response of
patients to neoadjuvant treatment have been undertaken [4–10],
a number of which were reviewed in [11]. Unfortunately, up to
now none of the published predictors have been applied in the
clinical setting. This lack of clinical implementation can be
attributed to the fact that the results that were reported in the
original papers are either not reproducible in external data sets or
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the fact that the reported accuracy is not high enough to be used in
clinical decision making.
The best performing predictor of chemotherapy response
published to date has an area under the receiver operator curve
(AUC) of 0.805 [8]. In a subsequent independent validation study,
AUCs of 0.711 (T-FAC treatment) and 0.584 (FAC treatment)
were achieved for this same predictor [12]. While this is an
improvement over previous attempts, the accuracy of this
predictor is insufficient for clinical decision making. In order for
a predictor to be useful in the clinic, it should have a high true
positive rate (sensitivity) and a high true negative rate (specificity).
How high ‘high’ should be depends on the clinical decision to be
made. For example, if a predictor is employed to predict whether a
chemotherapeutic treatment will benefit a specific patient, the
decision will have far reaching consequences. However, if no
alternative methods of predicting response to treatment are
available, any sensitivity and specificity rates better than random
will be useful. While it is very hard to set a specific required
minimal specificity and sensitivity rate, we believe at least 0.9
should be required for both (note that the specificity and sensitivity
determine the AUC). This predictor was trained on all available
samples in the training dataset, irrespective of breast cancer
subtype.
In this study, we set out to determine if we could increase the
accuracy of the chemotherapy response predictors by creating
predictors that are specific for each breast cancer subtype, instead
of a predictor that was trained on all subtypes combined. In order
to make sure that our results would not be biased towards a certain
type of methodology we included six feature selection approaches
and six classifiers. These methods reflect commonly used methods
in the context of class prediction. Additionally, to answer the
question of how generally applicable our results are, we included




For this study we selected three gene expression data sets, all
hybridized on either the Affymetrix HG U133A platform or the
Affymetrix HG U133 plus 2.0 platform. The three sets consisted of
the microarray quality control II (MAQC2) breast cancer dataset
[13]; a breast cancer dataset from the Department of Breast and
Endocrine Surgery of the Osaka University (BESOU) [14] and a
breast cancer dataset from the MD Anderson Cancer Center
(MDACC) [12]. For all three datasets, informed consent from the
included patients and approval from an ethics committee were
obtained (the University of Texas M.D. Anderson Cancer Center
ethical committee for the MAQC2 study, the Ethics Review
Committee at Osaka University Hospital for the BESOU dataset,
and the institutional review boards of each participating institution
for the MDACC study). These datasets are publicly available from
the Gene Expression Omnibus website (MAQC2 GEO ID is
GSE16716, BESOU GEO ID is GSE32646, and MDACC GEO
ID is GSE20271). From these sets we extracted the samples that
were treated with taxol followed by 5-fluorouracil, (Adriamycin or
Epirubicin), cyclophosphamide (T-FAC or T-FEC). Patients that
were treated with a regimen including trastuzumab or FAC alone
were removed from our dataset in order to get a more
homogeneous treatment group. After this selection the dataset
consisted of 394 samples in total. Unfortunately not all of these
had all clinical data available, so for analyses based on clinical
features the total dataset consisted of 374 samples. Table 1 and
Table S1 show an overview of the characteristics of this set of
patients.
In these datasets, a pathological complete response (pCR) was
defined as no residual invasive cancer in the breast and axillary
lymph nodes. Samples were defined to be ER-positive or PR-
positive when 10% or more of the tumor cells showed positive
staining of ER or PR respectively, based on immunohistochem-
istry. Samples were marked as positive for HER2 when there was
strong membrane staining (3+) or the sample had a gene copy
number equal to or greater than 2.0 as measured by Fluorescent
In Situ Hybridization (FISH ratio greater than 2.0 for the BESOU
dataset).
Data preparation
All datasets (raw data) were downloaded from GEO [15]. The
samples were background corrected and normalized using
GeneChip-RMA [16] and subsequently log2 transformed. Since
we combined datasets which originated from different experiments
and platforms we applied a normalization strategy to enable
reliable combination of the different datasets. First we verified the
individual probe quality by employing ProbeMapper [17]. We
selected the probes that were mapped to the same transcript by the
vendor, the bioconductor annotation packages and a BLAST
mapping of the probes to the set of transcripts of the latest human
genome build (Hg19). In addition, we discarded the probes that
were mapped to multiple genes. The probes that passed these tests
were median centered, i.e. we set the median expression of each
probe per dataset to match the median expression of that probe in
the MAQC2 dataset. The median centering was performed by
taking into consideration the ratio of clinical subtypes and
response rates in each dataset, i.e. the median expression of a
gene within a dataset was determined on a subset that was chosen
such that it matched the other datasets with respect to the
percentages of clinical subtypes and response rates. We chose the
largest possible subsets that satisfied these constraints. For the
subsequent analysis we selected the most informative probe per
gene, i.e. the probe which showed the highest standard deviation
across all data sets.
Feature selection and classification
After probe matching and gene median centering, 12010 genes
were entered into the subsequent analysis. In addition to
expression based predictors we also investigated the predictive
Table 1. Distribution of samples in the subgroups.
Stratification pCR (%) No pCR (%)
Clinical subtypes
HER2 positive 31 (38) 51 (62)
Luminal 14 (9) 185 (91)
Triple Negative 42(37) 71 (63)
HER2 positive, ER negative 25 (56) 20 (44)
HER2 positive, ER positive* 6 (16) 31 (84)
No stratification
All 87 (22) 307 (78)
The sample sizes that are depicted are from the expression based predictors.
The sample sizes for the clinical predictors are a bit lower due to missing data
and can be found in Table S1.
*The HER2 positive, ER positive group was not included in the analysis due to
the small sample size.
doi:10.1371/journal.pone.0088551.t001
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power of clinical features. For these predictors we selected ER
status, PR status, HER2 status, TNM-stage, age and grade as the
features to be used. All of these are routinely determined in the
clinic and were directly available in the datasets we selected.
We employed three feature selection approaches for the
expression based predictors and three for the clinical predictors.
We chose different feature selection approaches for the expression
and the clinically based predictors, since the expression features
are all continuous valued and most of the clinical features are
categorical, implying different requirements for feature selection.
The feature selection approaches employed by the expression
predictors were: Wilcoxon-Mann-Whitney test (WMW), Wil-
coxon-Mann-Whitney test after removal of features with a Pearson
correlation exceeding 0.75 (WMW-uncor.) and the ratio of
between- to within group sum of squares (BWR). These methods
are either available in R [18] or were implemented in R. The
ranking approaches employed for the clinical features were:
information gain (Inf.gain), correlation feature selection (CFS) and
RELIEF. These feature selection methods are available in the
‘‘FSelector’’ R package [19]. The features were ranked by their
respective scores when comparing responder samples to non-
respond samples (i.e. their discriminative power) in order to select
the best features for classification.
The classifiers that we employed were the same for the
expression data and the clinical data. We tested the following
classifiers: the J48 decision tree (J48), the 3-nearest neighbor
classifier (3NN) based on Euclidean space, the nearest mean
classifier (in Euclidean space), logistic regression (LREG), naive
Bayes (NB) and a support vector machine (SVM) (WeKa SMO
with default settings). This represents a wide range of classifiers
including linear and non-linear classifiers as well as classifiers
designed for discrete and continuous features. All classifiers were
implemented in the ‘‘RWeka’’ R package [20,21].
We implemented each possible combination of classifier and
feature ranking approach, except for the J48 classifier since this
classifier includes its own feature selection approach. This resulted
in 16 clinical and 16 expression based predictors. We will refer to a
specific combination of a set of selected features and the associated
classifier as a predictor.
Estimation of predictive performance
To estimate the accuracy of the predictors we employed the
AUC. The AUC is estimated through a double loop cross-
validation strategy, illustrated in Figure 1.
Full details of the procedure are outlined in the supplementary
materials and methods (Methods S1 and Figure S1), in summary
the following steps are taken: 1) the input dataset is divided into 2/
3 for the training set and 1/3 for the validation set; 2) the training
set (i.e. 2/3 of all data) is employed to determine the optimal
number of features to be used in each feature selection method
and classifier combination (i.e. for each of the 16 possible
combinations of feature selection method and classifier, a single,
optimal number of features is determined); 3) the training set is
then used to train each of the 16 predictors with the number of
features previously determined to be optimal for each combina-
tion; 4) finally the performance of each feature selection and
classifier combination is assessed by applying these 16 predictors to
the validation set (i.e. 1/3 of all data). The split into training and
validation sets was performed such that the ratios of subtypes and
response rates within the two sets were equal. This whole
procedure was repeated 15 times in order to get a more accurate
average performance per predictor and subtype. This double loop
cross-validation procedure is similar to the approach that was
employed by Popovici et al. [13] and Wessels et al. [22].
For the non-subtype specific predictors, we divided all data of all
subtypes into three equal parts, i.e. the dataset was subdivided into
2/3 of the samples in the training set and the remaining 1/3 in the
validation set. For the subtype specific predictors the input dataset
consisted only of samples of the specific subtype being analyzed
(i.e. the 2/3 training set and 1/3 validation set consisted only of
samples belonging to the relevant subtype). In order to compare
the performance of the non-subtype specific predictor with the
subtype specific predictor on a given subtype, say TN, the non-
subtype specific predictor was trained on a training set consisting
of all subtypes, but only validated on a the validation set consisting
of TN samples.
Finally we selected the best performing predictor per subtype for
both the subtype specific and the non-subtype specific predictors in
order to compare their performances. To compare the AUC
values of non-subtype specific predictors to the AUC values of
subtype specific predictors we employed the two-sided t-test.
Results
Subtype specific versus non-subtype specific predictors
We employed a stratification based on ER and HER2 status.
We stratified patients into a HER2 positive group (HER2+), a
Luminal group (HER22, ER+) and a Triple Negative group
(HER22, ER2)(TN). We further subdivided the HER2-positive
group based on ER status, resulting in a HER2-positive and ER-
negative group (HER2+, ER2) and a HER2-positive and ER-
positive group (HER2+, ER+). Unfortunately, the (HER2+, ER+)-
group contained too few samples to analyze this group separately
with adequate power (n = 37).
Figure 2 shows the comparison of the best performing classifiers
for the subtype specific and non-subtype specific predictors.
Predictors based on clinical features. The AUCs for the
clinical subtype specific and non-subtype specific predictors were
highly similar for most sets (HER2+, TN and ER+) (Red boxplots
in Figure 2). Only in the HER2+, ER2 subgroup there was a
significant difference, where the subtype specific predictor had a
significantly higher AUC than the non-subtype specific (multiple
testing corrected p-value: 4.361025). None of the other groups
showed a significant difference in AUC between the subtype
specific and non-subtype specific clinical predictors.
Predictors based on gene expression data. The AUC
comparisons for the expression based predictors (blue boxplots in
Figure 2) mostly mirrored the results for the clinical features based
predictors. All groups showed highly similar results for the subtype
specific and the non-subtype specific predictors. Only in the
Luminal group, a borderline significant difference in AUC
between the subtype specific and non-subtype specific predictor
was observed (corrected p-value: 0.0709).
Table 2 shows the best performing feature selection method-
classifier combination for each dataset (these correspond to
predictors whose AUCs were compared in Figure 2). The exact
average AUC scores and details about the different data sets can
be found in Table S2.
Discussion
From our analysis we can conclude that there is very little
difference in performance between building subtype specific
predictors compared to building non-subtype specific predictors
(i.e. combining data of all subtypes and training on that dataset).
This is true for the predictors employing clinical features as well as
the predictors employing gene expression predictors. We did
observe that in the Luminal subgroup all the non-subtype specific
Subtype Specific and Generic Classifiers Compared
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models (gene expression or clinical features based) tended to
achieve better AUC scores compared to the subtype specific
predictors, although this difference was not significant. The
Luminal group has been reported to consist of a combination of
two distinct intrinsic subtypes, Luminal A and Luminal B. This
further subdivision of the Luminal subtype could prove interesting,
since these subtypes were reported to show different response rates
following neoadjuvant treatment. Table S3, Table S4, and Figure
S2 show the results of our analysis of the Luminal intrinsic
subtypes, which were classified according to the ‘‘PAM50’’
predictor [23]. In the expression based model, we observed a
significant difference between the subtype specific predictor and
the non-subtype specific predictor in the Luminal A and Luminal
B subgroups. Analogous to the Luminal subgroup analysis, the
non-subtype specific predictors outperformed the subtype specific
predictors. This could be explained by the fact that positive events
(i.e. pathological complete responses) are rare in these sets (13, 13,
and 14 cases, corresponding to 9%, 13%, and 14% of the samples
showed a pCR in the Luminal A, Luminal B, and Luminal groups,
respectively). Having few samples in the minority class will make it
difficult to train a predictor that correctly classifies samples from
this minority class, leading to lower AUC values. The higher
performance of the non-subtype specific predictor (compared to
the subtype specific predictor) could be explained by the fact the
Figure 1. Cartoon of the double loop cross-validation scheme. Our analysis employed a double look cross-validation. The inner loop
determines the optimal number of features to be used by a specific combination of feature selection and classifier, here depicted by the green block.
This inner loop uses 2/3 of all data (i.e. the training data), the remaining 1/3 is employed to measure the performance of the trained classifier (i.e. a 3
fold cross-validation setup). The outer loop is repeated 15 times in order to get an average AUC for each predictor.
doi:10.1371/journal.pone.0088551.g001
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Figure 2. The AUC scores for the best performing predictors on each subtype. AUCs for the (A) HER2 positive subtype; (B) Luminal subtype;
(C) Triple negative subtype and (D) HER2 positive and ER negative subtype. The red bars represent the clinical predictors, blue bars the expression
based predictors and darker colors represent non-subtype specific predictors. When two boxplots are connected with a u-shaped line, the means of
the AUC distributions are significantly different for the experiment represented by the boxplots (two-sided t-test, p,0.05, Bonferroni multiple testing
corrected.)
doi:10.1371/journal.pone.0088551.g002
Table 2. Characteristics of the optimal predictors for the different subtypes.
Clinical Gene Expression
Stratification Subtype specific Non specific Subtype specific Non specific
Luminal LREG-Relief NM-Relief NM-WMW NB-BWR
Triple Negative NM- CFS NB-Relief NB-BWR LREG-WMW- uncor.
HER2-positive NB-Relief NB-CFS NB-WMW NB-WMW
HER2-positive, ER-negative 3NN-CFS NM-CFS NB-WMW LREG-BWR
In each cell the optimal combination of classifier, and feature selection method, is shown.
Legend: classifiers: NB=Naive Bayes, NM=Nearest Mean, LREG: Logistic regression, SVM= Support vector machine, 3NN=3-Nearest Neighbor; Feature selection
methods: CFS = Correlated feature selection, WMW=Wilcoxon-Mann-Whitney, BWR= Ratio between to within class sum of squares, WMW-uncor. =Wilcoxon-Mann-
Whitney where correlated features are removed, Inf.gain = information gain.
doi:10.1371/journal.pone.0088551.t002
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complete dataset on which it was trained has a higher (absolute)
number of samples in the minority class (i.e. responders), which in
turn might lead to better classification of samples in the minority
class in the validation set and a higher AUC as a result.
For the TN and HER2+ subtypes, there was no clear difference
between the subtype specific and the non-subtype specific
predictors. Only for the HER2-positive and ER-negative sub-
group, we found a significant difference in clinical feature based
predictor performance. The subtype specific predictor, based on
clinical features, was superior to the non-subtype specific model.
While the AUC of the subtype specific model was 0.59, the AUC
of the non-subtype specific model was exactly 0.5. This could be
explained by the fact that in most iterations of the predictor
training, the non-subtype specific predictor included only a single
feature. This single feature was ER status (in some cases combined
with either PR or HER2). Taken over the whole dataset, ER status
(or PR and HER2) is highly predictive of response to chemother-
apy. However, the HER2+, ER2 subtype is, by definition,
completely ER negative and HER2 positive, so the ER and
HER2+ status feature will not yield any predictive power in this
subgroup. The subtype specific predictor did not include ER or
HER2 status, but included age, stage and grade. Given that the
subtype specific predictor included more informative features, it
was no surprise that it could achieve higher AUC values. This
scenario forms a clear example of when a subtype specific
predictor is preferred, i.e. a feature is predictive over the whole
dataset, but is non-informative within a specific subgroup of that
dataset. When we look at the same subtype, but now employing
gene expression data, the difference between the subtype specific
and non-subtype specific predictors, however. The selected
features in that classifier are predictive over both the entire set
and this specific subgroup of samples.
In our analysis we did not take into account that there is a large
difference in the size of the training set between subtype specific
and non-subtype specific predictors. That is, we compared the
subtype specific predictors, the predictors based only on data from
one subtype, to a predictor that was trained on data from all
subtypes. This means that the training set sizes of the non-subtype
specific predictors were two to four times as large as the subtype
specific training sets (depending on the size of the subtype relative
to the whole dataset). These training set size differences have an
influence on predictor performance and performance estimation.
Since we focused on comparing subtype specific to non-subtype
specific predictors in real world situations, we opted to compare
performance in this manner. When a dataset is to be analyzed, one
would always want to use as much data as available so it would not
make sense to only take part of the combined dataset purely for
comparison reasons. Our results suggest that the larger training set
of the generic predictor outweighs the benefits of a subtype specific
training set. This in turn implies the important notion that there
are features in the data that can predict response to therapy that
are shared amongst different subtypes. That is, if there was no
commonality between predictive factors in the different subtypes,
the increased training set size would not increase the performance
of the generic predictor. It has been shown that patients benefit
from receiving subtype specific treatments instead of a general
treatment [24,25]. When patients receive treatment that is specific
for a particular subtype, a predictor that combines all data will not
only have to deal with heterogeneity in subtypes, but also in
treatment regimens received. It remains to be seen if a non-
subtype specific predictor will, in such a scenario, still perform as
well as a predictor that was trained for a specific treatment and
subtype.
In this study we combined publicly available datasets in order to
have as many samples as possible available for analysis. Since
treatment and microarray platform could potentially be major
confounders in an analysis such as the one we present here, we
opted to limit our dataset to samples from patients receiving
similar treatment and which were analyzed on the same
microarray platform. To account for institute specific confounders
(and consequently also genetic background confounders to a
degree, given that one institute is located in Japan and two
institutes procured samples from US and Europe), we normalized
our datasets by median centering per probe, per institute. Even
with these stringent criteria and normalization procedure,
confounding effects could not be ruled out. Until larger
homogeneous datasets become available, such potential confound-
ers will remain an issue.
In recent papers studying outcome prediction after T-FAC or
T-FEC and FAC or AC neoadjuvant therapy, no predictors
specific for breast cancer subtypes were built [4,8,9,13]. Therefore,
we cannot directly assess if the subtype specific predictors that we
built perform better or worse than previously published predictors.
However, we could compare the non-subtype specific predictors
(i.e. built and tested on all subtypes at once). More specifically, we
compared the performance of our predictors to the predictors
published alongside the three Affymetrix datasets which we
included in our study. Unfortunately, the paper that was published
alongside the BESOU data did not include AUC values so we
could not compare their performance to ours. Instead, the authors
of this paper [9], focused on finding the best model to achieve a
high negative predictive value instead of a high AUC. In the paper
accompanying the MAQC2 dataset [13], the authors presented an
expression based predictor that combined LREG with BWR. The
gene expression based predictor published with the MDACC
dataset [12], was a predictor based on DLDA (Naive Bayes (NB)),
which included 30 genes, selected based on the t-test p-value. The
average AUC of the Popovici et al. model was: 0.805, Tabchy et
al. reported an AUC 0.711 for the T-FAC treated samples. Our
highest average AUC value was 0.768 (NB with BWR using 30
features). Given the variance we observed around our AUC
estimate, these AUC values are most likely not statistically
significantly different.
Tabchy et al. also validated a nomogram based on clinical data,
which achieved an AUC of 0.89 for the T-FAC treatment arms.
Our best clinical feature predictor was the predictor employing
NB and relief using six features, which achieved an average AUC
of 0.796. Again, the variance of the double loop CV estimate is of
such a magnitude that these values are most likely not significantly
different.
A possible explanation for the slightly lower AUC values for our
predictors could lie in the fact that we classified more samples and
-potentially- our AUC estimates are more accurate due to our
larger sample set. We included 2.9 times as many samples
compared to Tabchy et al. and 1.7 times as many samples
compared to Popovici et al. In addition, we combined data from
multiple sets and even though the patient characteristics were not
significantly different, this could have an influence on the AUC.
Differences in estimated AUC values could also be attributed to
the training and validation procedures employed. To test this we
applied our double-loop cross validation on the Tabchy and
Popovici datasets. Our best performing gene expression based
predictors showed AUCs of 0.807 and 0.780 respectively, which is
very close to the reported performances. This indicates that the
published performances are robust, but dataset specific. As we
trained and tested on a larger dataset, and as the training and
testing procedure has been proven to be robust, our achieved
Subtype Specific and Generic Classifiers Compared
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AUC of 0.768 is probably closer to the real value. However, as
indicated above, these values are within the error margins of the
experiments and since we compared the relative performance of
specific to generic predictors, this performance difference has no
consequences for the results presented here.
Conclusions
In general, subtype specific predictors would be preferred over
non-subtype specific predictors. However, when the phenotype to
be predicted has a skewed distribution, like response in the
Luminal subtype, a non-subtype specific predictor (i.e. based on all
data combined) will outperform the subtype specific predictor.
This implies that there are features that are predictive of response
to chemotherapy that are shared amongst different subtypes and
resistance mechanisms are not exclusive to particular subtypes. In
specific cases where features are predictive over the whole dataset,
but uninformative within a specific subgroup, like ER and HER
status in the HER2-positive and ER-negative subgroup, a subtype
specific predictor will offer a significant performance gain over
non-subtype specific predictors.
For breast cancer specifically - with the exception of the HER2-
positive, ER-negative group -, we can conclude that building a
subtype specific predictor offers equal performance compared to a
predictor based on all available data. However, when it is
unknown which of the scenarios mentioned above is present in the





Figure S1 Illustration of the double loop cross-validation
scheme. Legend: 3FCV: 3 fold cross-validation, CFS: Correlated
feature selection method, Inf.gain = information gain,
WMW = Wilcoxon-Mann-Whitney test, WMW-uncor. = Wil-
coxon-Mann-Whitney with correlated features removed,
BWR = between to within group sum of squares. NMC = nearest
mean classifier, LREG = logistic regression, NB = naı¨ve Bayes,
3NN = k-nearest neighbor, SVM = support vector machine.
(TIF)
Figure S2 AUCs for the (A) Luminal A subtype; (B) Luminal B
subtype. The red bars represent the clinical predictors, blue bars
the expression based predictors and darker colors represent non-
subtype specific predictors. When two boxplots are connected with
a u-shaped line, the means of the AUC distributions are
significantly different for the experiment represented by the
boxplots (two-sided t-test, p,0.05, Bonferroni multiple testing
corrected.)
(TIF)
Table S1 Basic description of the dataset used to analyze the
influence of subtype specific versus the non-subtype specific
models for predicting outcome after treatment. There is a small
difference in samples size for the clinical versus the expression
based model as there are some samples which lack description of
clinical features.
(XLSX)
Table S2 AUC values for the models that were included in the
analysis. Each tab of the excel file describes a different set of
models. The different models are in the rows and the different
subtypes are next to each other.
(XLSX)
Table S3 Distribution of samples in the Luminal A and Luminal
B subtypes. The sample sizes shown are the sample sizes as
employed by the expression based predictors. The sample sizes of
the clinical predictors were a bit lower due to missing data and can
be found in Table S1.
(DOCX)
Table S4 Characteristics of the optimal predictors for the
different subtypes. In each cell the optimal combination of
classifier, and feature selection method, is shown. Legend:
classifiers: NB = Naive Bayes, NM = Nearest Mean, LREG:
Logistic regression, SVM = Support vector machine, 3NN = 3-
Nearest Neighbor; Feature selection methods: CFS = Corre-
lated feature selection, WMW = Wilcoxon-Mann-Whitney,
BWR = Ratio between to within class sum of squares, WMW-
uncor. = Wilcoxon-Mann-Whitney where correlated features are
removed, Inf.gain = information gain.
(DOCX)
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